Andrea Lee Small – Howard
Company: GBS Global Biopharma, Inc./ GB Sciences, Inc.
Job title: Chief Science Officer, Director & Board Member
Dr. Andrea Small-Howard leverages broad biopharmaceutical industry knowledge and contacts in her current roles as Chief Science Officer and member of the Board of Directors at GBS Global Biopharma, Inc. (GBS). Dr. Small-Howard brings to GBS her passion for advancing clinical research on medicinal applications of cannabinoid compounds, pre-clinical experience in conducting cannabinoid research, a track record of successes in the management of biopharmaceutical companies, and a strategic vision for creating a novel drug discovery engine and biopharmaceutical drug development program for disease-specific, cannabis-based therapeutics.
Dr. Small-Howard has more than 20 years’ experience studying cannabinoids and the endocannabinoid system, immunology and cancer treatments; as well as executive experience in the biopharmaceutical industry where she supervised research and development, manufacturing and quality control divisions in both US and global divisions. She took the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration (“US FDA”) and numerous international regulatory agencies.
As a post-doctoral fellow, Dr. Small-Howard led a project group dedicated to the study of cannabinoids in the immune system. At AMDL, Inc., she took the lead in every stage of biotech product development from discovery through commercialization. As VP Scientific Oversight at Radient Pharmaceuticals Corp., she provided strategic product development and regulatory oversight across multiple international business divisions.